News

Aurobindo arm’s biosimilar for breast cancer gets EMA panel nod
Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.
Zymeworks Inc.: Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...
Writing Strong Antibody Claims: Avoiding or Addressing USPTO Rejections for Written Description and Enablement
Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...
Special Writer, The Wall Street Journal
Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
ADC assay now available through ABS; customer study proves IO60 is a spatial workhorseMARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology ...